A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.
ISS-IP1 Clinical Investigators. Floridia M, Tomino C, Bucciardini R, et al.
AIDS Res Hum Retroviruses 2000 Nov 20;16(17):1809-20
Abstract

Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals.
German Ritonavir/Indinavir Study Group. Rockstroh JK, Bergmann F, Wiesel W, et al. 
AIDS 2000 Jun 16;14(9):1181-5  
Abstract

RTV/IND/DVD/NRTIs

        Switching Therapy

FULL-TEXT PDF ARTICLE Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse  transcriptase inhibitors in patients with hiv/aids who have failed multiple antiretroviral combinations. Grodesky M, Acosta EP, Fujita N et al HIV Clin Trials 2001 May-Jun;2(3):193-9 PDF Paper

                    

RTV/IND/ZDV/3TC

          Dose Finding Study

Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients.
Mallolas J, Blanco JL, Sarasa M, et al.. 
J Acquir Immune Defic Syndr 2000 Nov 1;25(3):229-35 
Abstract

Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy
administered for 48 weeks.
Raines CP, Flexner C, Sun E, et al.
J Acquir Immune Defic Syndr 2000 Dec 1;25(4):322-8 
Abstract 

                           
RTV vs NFV vs EFV + one protease inhibitor

Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir,or efavirenz.
Lucas GM, Chaisson RE, Moore RD.
AIDS 2001 Sep 7;15(13):1679-1686
Abstract

A drug interaction between fusidic acid and a combination of ritonavir and saquinavir.
Khaliq Y, Gallicano K, Leger R, Foster B, et al.
Br J Clin Pharmacol 2000 Jul;50(1):82-3
Abstract 

Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.
Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N
Br J Clin Pharmacol 2000 Aug;50(2):99-107
Abstract

Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.
Kravcik S, Gallicano K, Roth V, et al.
Acquir Immune Defic Syndr 1999 Aug 15;21(5):371-5
Abstract

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir
therapy in patients in whom previous inhibitor therapy had failed.
Zolopa AR, Shafer RW, Warford A,  et al.  
Ann Intern Med 1999 Dec 7;131(11):813-21
Abstract 

Risk Factors for Hepatotoxicity in HIV-1-Infected Patients Receiving Ritonavir and Saquinavir with or without Stavudine. 
Gisolf EH, Dreezen C, Danner SA, et al. 
Clin Infect Dis 2000 Nov;31(5):1234-1239
Abstract

Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
Rockstroh JK, Bergmann F, Wiesel W, et al.
AIDS 2000 Jun 16;14(9):1181-5
Abstract

The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine.
Prometheus Study Group. Gisolf EH, Jurriaans S, Pelgrom J, et al. 
AIDS 2000 Mar 10;14(4):405-13
Abstract

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in
patients in whom previous protease inhibitor therapy had failed.
Zolopa AR, Shafer RW, Warford A, et al. 
Ann Intern Med 1999 Dec 7;131(11):813-21  
Abstract

Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy.
The Prometheus Study Group. Nieuwkerk PT, Gisolf EH, Colebunders R, et al. 
AIDS 2000 Jan 28;14(2):181-7  
Abstract 

FULL-TEXT ARTICLE
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
Michelet C, Ruffault A, Sebille V, et al.
Antimicrob Agents Chemother 2001Dec;45(12):3393-402
Paper

The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/and ritonavir/saquinavir/stavudine.
Prometheus Study Group. Gisolf EH, Jurriaans S, Pelgrom J, et al.
AIDS 2000 Mar 10;14(4):405-13  
Abstract

Assessing efficacy by measuring CD(4) counts and quality of life of AIDS patients treated with ritonavir, AZT and 3TC.
de Andrade JL Neto, Focaccia Siciliano R
Braz J Infect Dis 2000 Aug;4(4):173-82  
Abstract

Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315. 
ACTG Protocol 315 Team. Kuritzkes DR, Sevin A, Young B, et al.
J Infect Dis 2000 Feb;181(2):491-7  
Abstract 

Assessing efficacy by measuring CD(4) counts and quality of life of AIDS patients treated with ritonavir, AZT and 3TC.
de Andrade JL Neto, Focaccia Siciliano R
Braz J Infect Dis 2000 Aug;4(4):173-82  
Abstract